<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947385</url>
  </required_header>
  <id_info>
    <org_study_id>IDE196-001</org_study_id>
    <nct_id>NCT03947385</nct_id>
  </id_info>
  <brief_title>Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions</brief_title>
  <official_title>A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDEAYA Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDEAYA Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety
      and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11
      (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous
      melanoma, colorectal cancer, and other solid tumors.

      Phase 1 (dose escalation) will assess safety, tolerability and pharmacokinetics of IDE196 via
      standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and
      anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting Toxicity (DLT)</measure>
    <time_frame>28 days following first dose of IDE196</time_frame>
    <description>Determine DLT of IDE196</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 days following first dose of IDE196</time_frame>
    <description>Determine MTD of IDE196</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Approx. 6 months</time_frame>
    <description>Determine RP2D of IDE196</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of IDE196</measure>
    <time_frame>Cycle 1 Day 1 (C1D1), C1D15, C2D1, C3D1, C4D1, C5D1, C6D1</time_frame>
    <description>Pharmacokinetics of IDE196</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) in Dose Expansion</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>Approx. 30 months</time_frame>
    <description>RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Participants with Adverse Events</measure>
    <time_frame>Approx. 48 months</time_frame>
    <description>Safety and tolerability of IDE196</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approx. 48 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Approx. 48 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Metastatic Uveal Melanoma</condition>
  <condition>Cutaneous Melanoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDE196 dosed orally, twice daily (BID) for each 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP2D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDE196</intervention_name>
    <description>IDE196 dosed orally, twice daily for each 28-day cycle</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be ≥18 years of age

          -  Diagnosis of one of the following:

               -  MUM: Uveal melanoma with histological or cytological confirmed metastatic
                  disease. Or

               -  Non-MUM: Advanced cutaneous melanoma, colorectal cancer, or other solid tumor
                  that has progressed following prior standard therapies or that has no
                  satisfactory alternative therapies and has evidence of GNAQ/11 hotspot mutation

          -  Measurable disease

          -  Eastern Cooperative Oncology Group ≤1

          -  Adequate organ function at screening

          -  Adequate contraceptive measures for non-sterilized male and female patients of
             childbearing potential

        Exclusion Criteria:

          -  Another malignancy

          -  Known microsatellite instability-high (MSI-H) tumors

          -  Adverse events from prior anti-cancer therapy that have not resolved

          -  Untreated or symptomatic central nervous system metastases

          -  Human immunodeficiency virus, acquired immunodeficiency syndrome related illness,
             hepatitis B virus, or hepatitis C virus

          -  Recent surgery or radiotherapy

          -  Females who are pregnant or breastfeeding

          -  Impaired cardiac function

          -  Allergy to mammalian meat or gelatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>IDEAYA Clinical Trials</last_name>
    <phone>+1 650 534 3616</phone>
    <email>IDEAYAClinicalTrials@ideayabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center - Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Carvajal, MD</last_name>
      <phone>646-317-6330</phone>
      <email>rdc2150@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Melendez</last_name>
      <email>Sarah.melendez@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Y Perez, BS, CCRP</last_name>
      <email>Cynthia.Perez@jefferson.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute/Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>askSARAH</last_name>
      <phone>844-482-4812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Janku, MD</last_name>
      <phone>713-792-6161</phone>
      <email>FJanku@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Carlino, MD</last_name>
      <phone>+61 288 905 200</phone>
    </contact>
    <contact_backup>
      <phone>02 8890 5200</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

